Lactylation-augmented DCBLD1-mediated PDIA3 stabilization reprograms glycolysis metabolism in oesophageal cancer

OBJECTIVE: Histone lactylation (Hla) represents a novel epigenetic mark priming cells toward the malignant state. Discoidin, CUB, and LCCL domain-containing type I (DCBLD1) has been reported as a carcinogenic gene so far. This project was focused on the functional role of DCBLD1 in oesophageal cancer through the lactate modification pathway. METHODS: Biological information evaluated DCBLD1, protein disulfide isomerase family A member 3 (PDIA3) expression and the relationship between the two in oesophageal cancer. RT-qPCR and Western blotting were used to detect DCBLD1 and PDIA3 expression. Western blotting also quantified DCBLD1-lysine lactylation (kla) levels. DCBLD1 half-life was checked by chlorhexidine (CHX) assay. EDU, wound healing, transwell, flow cytometry and Seahorse assays individually appraised cell proliferation, migration, apoptosis and glycolysis. Co-IP assay identified DCBLD1-PDIA3 interaction. Xenografted tumorigenesis was estimated, prior to histological assessment by H&E staining. Glucose consumption and lactate production were also examined to detect glycolysis. RESULTS: DCBLD1 was highly expressed in esophageal cancer specimens and cells. DCBLD1 half-life was respectively shortened or prolonged in tumor cells challenged with lactate (LA) or the aerobic glycolysis inhibitor 2-deoxy-d-glucose (2-DG). DCBLD1-Kla levels were up-regulated in oesophageal cancer tissues. Lactate dehydrogenase A (LDHA) interference decreased both DCBLD1 expression and DCBLD1-Kla expression. PDIA3 was highly expressed in oesophageal cancer. DCBLD1 was positively correlated with, and interacted with PDIA3 upon LA stimulation. DCBLD1 knockdown inhibited cell proliferation, migration, glycolysis and induced apoptosis, repressed tumor progress and glycolysis in vivo, which were all partially recovered by PDIA3 overexpression. Further LDHA down-regulation aggravated the impacts of DCBLD1 knockdown and PDIA3 overexpression both in vitro and in vivo. CONCLUSION: It was established that DCBLD1 lactylation bound to PDIA3, contributing to oesophageal cancer malignancy and glycolysis.

Authors

Institutions

Publication Details

Journal
Journal of Cancer Research and Clinical Oncology
Published
2026-05-31
DOI
https://doi.org/10.1007/s00432-026-06517-6
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lactylation-augmented DCBLD1-mediated PDIA3 stabilization reprograms glycolysis metabolism in oesophageal cancer

Haimin Liu, Yunhao Sun, WANG Shan, Chaochen Xu et al.
Journal of Cancer Research and Clinical Oncology
Cancer, Hypoxia, and Metabolism
article

Lactylation-augmented DCBLD1-mediated PDIA3 stabilization reprograms glycolysis metabolism in oesophageal cancer

Haimin Liu, Yunhao Sun, WANG Shan, Chaochen Xu, Qiushuo Li, Ming Yin
article en

Abstract

OBJECTIVE: Histone lactylation (Hla) represents a novel epigenetic mark priming cells toward the malignant state. Discoidin, CUB, and LCCL domain-containing type I (DCBLD1) has been reported as a carcinogenic gene so far. This project was focused on the functional role of DCBLD1 in oesophageal cancer through the lactate modification pathway. METHODS: Biological information evaluated DCBLD1, protein disulfide isomerase family A member 3 (PDIA3) expression and the relationship between the two in oesophageal cancer. RT-qPCR and Western blotting were used to detect DCBLD1 and PDIA3 expression. Western blotting also quantified DCBLD1-lysine lactylation (kla) levels. DCBLD1 half-life was checked by chlorhexidine (CHX) assay. EDU, wound healing, transwell, flow cytometry and Seahorse assays individually appraised cell proliferation, migration, apoptosis and glycolysis. Co-IP assay identified DCBLD1-PDIA3 interaction. Xenografted tumorigenesis was estimated, prior to histological assessment by H&E staining. Glucose consumption and lactate production were also examined to detect glycolysis. RESULTS: DCBLD1 was highly expressed in esophageal cancer specimens and cells. DCBLD1 half-life was respectively shortened or prolonged in tumor cells challenged with lactate (LA) or the aerobic glycolysis inhibitor 2-deoxy-d-glucose (2-DG). DCBLD1-Kla levels were up-regulated in oesophageal cancer tissues. Lactate dehydrogenase A (LDHA) interference decreased both DCBLD1 expression and DCBLD1-Kla expression. PDIA3 was highly expressed in oesophageal cancer. DCBLD1 was positively correlated with, and interacted with PDIA3 upon LA stimulation. DCBLD1 knockdown inhibited cell proliferation, migration, glycolysis and induced apoptosis, repressed tumor progress and glycolysis in vivo, which were all partially recovered by PDIA3 overexpression. Further LDHA down-regulation aggravated the impacts of DCBLD1 knockdown and PDIA3 overexpression both in vitro and in vivo. CONCLUSION: It was established that DCBLD1 lactylation bound to PDIA3, contributing to oesophageal cancer malignancy and glycolysis.

Journal of Cancer Research and Clinical Oncology
Xuzhou Medical College (CN), Nantong University (CN), Yancheng First People's Hospital (CN), Binzhou People's Hospital (CN)
Good health and well-being
Openalex Percentile: Top 7%
Cancer, Hypoxia, and Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.